Across our cohort, TP53 alterations were associated with resistance in all cancer types which is consistent with TP53 mutations as mechanisms of resistance to chemotherapy, the mainstay of treatment for PDAC, CCA, and EGCs38. The gene discussed is TP53; the disease is cancer.